ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company that is a pioneer in the development and commercialization of high-performance and cutting edge life science research instrumentation. ACEA’s mission is to transform cell-based assays by providing innovative and cutting edge products and solutions to the research and drug discovery community. ACEA launched its first product for real-time, label-free cell-based assays based on a microelectronic readout in 2004. Today, the company has a product line of six instruments which utilize this technology with different functionalities and throughputs, and enables different types of cell-based applications. The application range is broad and diverse, covering all aspects of pre-clinical drug discovery and development as well as toxicity and safety pharmacology. The xCELLigence instruments are also well utilized in basic academic research in the cancer and toxicity areas. The citation of the xCELLigence system in over 400 peer reviewed publications from the pharmaceutical industry and academia is a testament to the success and uptake of this platform in different life science applications. ACEA was founded in 2002, is headquartered in San Diego, CA and has world-class manufacturing operations in Hangzhou, China. With its international reach, ACEA continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.
Website: www.aceabio.com